Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of Opioid Use Disorder and Non-fatal Overdose on Tau Pathology
NCT05651516Phase 1Completed
- Sponsor
- University of Pennsylvania
- Start
- Sep 2023
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of 18F-PI-2620 in opioid use disorder (OUD) (3 arms), sponsored by University of Pennsylvania. Primary endpoint: Standardized Uptake Value Ratio at 8 weeks. Started Sep 2023; status: completed.
02
Drugs
18F-PI-2620
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT05651516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05651516.